it was the MF's article written by AF (Adam Feustein) suggesting to have a Bio IMMU index which ADXS is one of the 20 biotech stocks.. I have been tracking it since $9.. but was too busy investing in CLDX, AGEN, ZIOP.. tracking ADXS, NWBO and other bios until stock price pulls back to the demand zone which ADXS is building the base now.
In addition, yesterday's CC was positive on clinical trials roadmaps, good progress on partnership front, and upcoming potential for IP's revenues..
It is a great gift to buy in @$18.75 after the yesterday 7% drop .. my stop loss is $18.25 (-3%) if it continues to drop, but I would expect ADXS market caps to be higher than $1Bil by the end of Q4-15... GL
the good, the bad or the ugly news, he's obligated by laws to communicate to shareholders in a timely manner.. expecting the worse, but hope for the best.. GL longs..
fair assessment.. 15% shares diluted, with the current market caps of $470 Mil, AGEN should be traded around $5.50ish until the major positive news is announcement or BO.. there's no reason to buy in higher than $6. gl
if you signed an exclusive deal and don't get a huge amount of money upfront, then you're giving IPs away.. JnJ payouts were based on the contingency of getting the FDA approval and sale of drugs which will not happen for another 2 years.. IPs transfer process will be completed in a few months...
ACHN investors get fecked big time..
WS is a corrupted institution.. these crooks should be locked up in an institution.. wonder why they call themselves as institutional investors.. simply because they are crooked.
if JnJ spends $225MILLION / 18.4Million shares = $12.25 this week, then it is a good deal for ACHN.
If JnJ only acquired 18.4 Mil shares @$12.25 after the FDA approval, then ACHN management is giving IPs away for nothing.. This deal is NOT good for the current shareholders, this deal is only good for ACHN management because they will loot this cash by giving themselves huge bonuses and stock options for completing this deal with JnJ... gradually, stock price will going lower.. until the FDA approval.. GL
milestone payments are still few years away, including sales & FDA approvals.. but technology transfer will happen within months... no timeline was specified for $225Mil equity investment which means JnJ can delayed until they can maximize their investments.. after the technology transferred, ACHN is finished..
ACHN get no payment upfront before the technology transfer process.. this is NOT smart move by the ACHN leadership team.. similar exclusive deal happened to MNKD and SNY, MNKD stocked dropped more than 60% after the announcement, expecting the same with this deal..
exclusive licencing means, JnJ will drive the value to the ground so they don't have to payout the milestones while acquired the IP to develop other drugs using the ACHN platform for free.. this mgtment team is not watching out for shareholders value.. they were watching out for their own paid out.. feck this #$%$.. another bio-scam..
let me know how many shares do you like to short and I will be selling them to you.. it just jumped to 10.85.. 15 cents more and your wishes will be fulfilled..
you can either short this stock or stop making mindless speculations without logic behind your numbers. you need to grow up..